Adults with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS) experience significantly shorter survival after treatment with immune checkpoint inhibitors (ICIs) and receive ICIs more often than those with better performance status, according to a study published in Cancer.
The researchers indicated that these findings align with prior retrospective evidence suggesting the need for the incorporation of adults with performance status ≥2 into randomized clinical trials.
“This collective evidence helps clarify that survival outcomes from pivotal phase III clinical trials of ICIs may not be generalizable to adults with impaired PS,” the authors wrote. “Therefore, caution should be used in counseling functionally impaired adults who are facing decisions about whether to pursue ICI treatment for advanced NSCLC.”
In this retrospective, single-site…
